AI Article Synopsis

  • The study aimed to explore the effects of L-carnitine on metabolic steatohepatitis in mice fed a high-fat diet, as there is no established pharmacological treatment for this condition.
  • Mice supplemented with L-carnitine showed improvements such as decreased body weight gain, prevention of liver fat accumulation, and enhanced liver health despite the ongoing high-fat diet.
  • The results suggest that L-carnitine might help treat metabolic syndrome by improving mitochondrial function, insulin signaling, and reducing fat production in the liver.

Article Abstract

Aim: Pharmacological treatment for metabolic syndrome-related non-alcoholic steatohepatitis has not been established. We investigated the effect of L-carnitine, an essential substance for β-oxidation, on metabolic steatohepatitis in mice.

Methods: Male KK-A mice were fed a high-fat diet (HFD) for 8 weeks, with supplementation of L-carnitine (1.25 mg/mL) in drinking water for the latter 4 weeks.

Results: Serum total carnitine levels were decreased following HFD feeding, whereas the levels were reversed almost completely by L-carnitine supplementation. In mice given L-carnitine, exacerbation of hepatic steatosis and hepatocyte apoptosis was markedly prevented even though HFD feeding was continued. Body weight gain, as well as hyperlipidemia, hyperglycemia, and hyperinsulinemia, following HFD feeding were also significantly prevented in mice given L-carnitine. High-fat diet feeding elevated hepatic expression levels of carnitine palmitoyltransferase 1A mRNA; however, production of β-hydroxybutyrate in the liver was not affected by HFD alone. In contrast, L-carnitine treatment significantly increased hepatic β-hydroxybutyrate contents in HFD-fed mice. L-carnitine also blunted HFD induction in sterol regulatory element binding protein-1c mRNA in the liver. Furthermore, L-carnitine inhibited HFD-induced serine phosphorylation of insulin receptor substrate-1 in the liver. L-carnitine decreased hepatic free fatty acid content in 1 week, with morphological improvement of swollen mitochondria in hepatocytes, and increases in hepatic adenosine 5'-triphosphate content.

Conclusions: L-carnitine ameliorates steatohepatitis in KK-A mice fed an HFD, most likely through facilitating mitochondrial β-oxidation, normalizing insulin signals, and inhibiting de novo lipogenesis in the liver. It is therefore postulated that supplementation of L-carnitine is a promising approach for prevention and treatment of metabolic syndrome-related non-alcoholic steatohepatitis.

Download full-text PDF

Source
http://dx.doi.org/10.1111/hepr.12720DOI Listing

Publication Analysis

Top Keywords

l-carnitine
12
kk-a mice
12
hfd feeding
12
mice l-carnitine
12
metabolic steatohepatitis
8
treatment metabolic
8
metabolic syndrome-related
8
syndrome-related non-alcoholic
8
non-alcoholic steatohepatitis
8
mice fed
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!